Takahashi Yuki, Adachi Hirofumi, Mizukami Yasushi, Yokouchi Hiroshi, Oizumi Satoshi, Watanabe Atsushi
Department of Thoracic Surgery, National Hospital Organization, Hokkaido Cancer Center, Sapporo, Japan.
Department of Thoracic Surgery, Sapporo Medical University, School of Medicine and Hospital, Sapporo, Japan.
J Thorac Dis. 2019 Sep;11(9):3836-3845. doi: 10.21037/jtd.2019.09.17.
The efficacy of curative-intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with certain types of oligometastases, particularly brain and adrenal metastases, has previously been described. We investigated the outcomes of curative-intent pulmonary resection for NSCLC patients with synchronous isolated bone metastases, which have been less clear to date.
We retrospectively reviewed the clinical and pathological records of 41 patients with NSCLC and synchronous isolated bone metastases who underwent radical treatments (surgery and/or chemotherapy and/or radiotherapy) for both their primary tumors and bone metastases at the National Hospital Organization, Hokkaido Cancer Center, between 2008 and 2013.
Nine of the 41 patients underwent pulmonary primary tumor resection; the rate of clinical N0-1 disease among these 9 patients (100%) was significantly higher than that among the 32 patients who did not undergo resection (34.4%). The five-year overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) rates of the nine patients who underwent pulmonary resection were 66.7%, 55.6%, and 44.4%, respectively. On multivariate analysis, the predictors of longer OS among all 41 patients were primary site resection [hazard ratio (HR) =4.18, 95% CI, 1.20-14.6, P=0.025] and epidermal growth factor receptor (EGFR) mutation (HR =3.30, 95% CI, 1.08-10.1, P=0.036). The former was also a predictor of longer PFS (HR =3.75, 95% CI, 1.27-11.0, P=0.016).
Patients with clinical N0-1 NSCLC and synchronous isolated bone metastases may achieve longer survival rates following primary lung tumor resection.
先前已描述了根治性肺切除术对某些类型寡转移的非小细胞肺癌(NSCLC)患者的疗效,特别是脑转移和肾上腺转移患者。我们研究了根治性肺切除术对同步孤立骨转移的NSCLC患者的疗效,迄今为止,其疗效尚不清楚。
我们回顾性分析了2008年至2013年期间在北海道癌症中心国立医院组织接受原发性肿瘤和骨转移瘤根治性治疗(手术和/或化疗和/或放疗)的41例NSCLC和同步孤立骨转移患者的临床和病理记录。
41例患者中有9例接受了肺原发性肿瘤切除术;这9例患者(100%)的临床N0-1期疾病发生率显著高于未接受切除术的32例患者(34.4%)。接受肺切除术的9例患者的五年总生存率(OS)、无进展生存率(PFS)和无病生存率(DFS)分别为66.7%、55.6%和44.4%。多因素分析显示,所有41例患者中,总生存期较长的预测因素为原发部位切除[风险比(HR)=4.18,95%可信区间(CI),1.20-14.6,P=0.025]和表皮生长因子受体(EGFR)突变(HR =3.30,95%CI,1.08-10.1,P=0.036)。前者也是无进展生存期较长的预测因素(HR =3.75,95%CI,1.27-11.0,P=0.016)。
临床N0-1期NSCLC和同步孤立骨转移患者在原发性肺肿瘤切除术后可能获得更长的生存率。